Meeting
2011 ASCO Annual Meeting
Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer.
Authors
J. Yang
Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China
J. Yang , X. Zhang , J. Su , H. Chen , H. Tian , Y. Huang , C. Xu , Y. L. Wu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Tumor Biology
Track
Tumor Biology
Sub Track
Molecular Targets
Citation
J Clin Oncol 29: 2011 (suppl; abstr 10517)
Abstract #
10517
Poster Bd #
9
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
Association of KRAS mutations in cell-free circulating tumor DNA with occurrence of resistance to TKIs in NSCLC.
First Author: Marzia Del Re
Poster
2021 ASCO Annual Meeting
Activity of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) in patients (pts) with NSCLC with uncommon EGFR mutations: A real-world cohort study (UpSwinG).
First Author: Satoru Miura
Poster
2019 ASCO Annual Meeting
Mutation and treatment profiles of patients with concurrent EGFR and ALK actionable mutations (muts).
First Author: Jun Zhao
Poster
2017 ASCO Annual Meeting
Investigating novel resistance mechanisms to third generation EGFR TKI osimertinib in non-small cell lung cancer patients using next generation sequencing.
First Author: Qiuxiang Ou